Immunology

all catalysts(0)

nothing on the calendar yet

News(10)

• Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
  CEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.
  biospace · 8h ago
• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 2d ago
• Foghorn cuts 40% of workforce
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2d ago
• ‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipeline
  When Xaira Therapeutics first debuted in 2024 with a gobsmacking $1 billion in funding, a natural expectation would have been for a flurry of further activity to follow. Instead, the buzzy AI biote…
  fiercebiotech · 3d ago
• Sanofi, Regeneron broaden alliance to find their next Dupixent
  The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.
  biopharma_dive · 3d ago
• Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
  Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’…
  biospace · 3d ago
• Pfizer’s eczema drug clears skin in mid-stage trial
  Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.
  biopharma_dive · 3d ago
• Foghorn lays off 40% of staff after Lilly collaboration ends
  Foghorn Therapeutics and Eli Lilly teamed up in 2021 to develop and commercialize oncology products. The biotech’s layoffs will leave the company with 65 employees as it refocuses on its proprietar…
  biospace · 3d ago
• Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
  Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…
  biospace · 3d ago
• STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy
  Questions about the durability of an experimental Huntington's disease therapy matter to Wall Street. They matter less to those directly affected by the disease.
  stat · 4d ago